skip to main content

Low-risk Endometrial No Adjuvant — SCE Medical Oncology MCQ

Instant feedback + full explanation. One question, done properly.

HardGynaecological CancersLow-risk Endometrial No AdjuvantSCE Medical Oncology

A patient has newly diagnosed primary stage IVB endometrial carcinoma that is microsatellite stable and mismatch-repair proficient. She is fit for systemic treatment and has not previously received chemotherapy for advanced disease. Which statement reflects the current NICE TA1117 position?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Dostarlimab plus platinum-containing chemotherapy can be used in this MMR-proficient population

Option B is correct: TA1117 specifically permits dostarlimab plus platinum-containing chemotherapy for primary advanced or recurrent MSS/MMRp endometrial cancer. Option C confuses this appraisal with earlier biomarker-restricted indications. Option A is now too restrictive. Option E omits the chemotherapy backbone, and option D incorrectly excludes chemotherapy and immunotherapy on biomarker grounds.

Reference: NICE TA1117: dostarlimab plus platinum chemotherapy in MMR-proficient endometrial cancer. https://www.nice.org.uk/guidance/ta1117/chapter/1-Recommendations